Email Alert | RSS    帮助

中国防痨杂志 ›› 2003, Vol. 25 ›› Issue (5): 318-320.

• 论著 • 上一篇    下一篇

抗结核药对乙肝与丙肝病毒重叠感染者肝功能的影响

蒙志好;   

  1. 广西胸科医院 柳州 545005;
  • 出版日期:2003-05-10 发布日期:2003-11-03

Effect of antituberculosis drugs on liver functions of the tuberculosis patient complicated with both hepatitis B and hepatitis C virus infectious

MENG Zhi-hao.   

  1. Guangxi Chest Hospital,Liuzhou 545005
  • Online:2003-05-10 Published:2003-11-03

摘要: 目的 探讨抗结核药对乙肝与丙肝病毒重叠感染者肝功能的影响。方法 对乙肝与丙肝病毒重叠感染者(观察组),在抗结核治疗过程中肝功能的变化情况进行分析,以同期采用同样治疗方案的2种肝炎病毒均阴性(对照组)者的肝功能作为对照。结果 观察组肝损害率(50.0%)明显高于对照组(7.7%),差异有高度显著性(P<0.01),其出现的时间、恢复正常时间两组差异亦有显著性(P<0.05、P<0.01),严重程度两组差异无显著性(P>0.05)。结论 乙肝与丙肝病毒重叠感染者在抗结核治疗过程中肝功能损害发生率高,出现早,恢复慢,但程度不一定重,应注意短期内监测肝功能。

关键词: 结核,肺, 肝炎病毒标记物,乙型, 肝炎病毒标记物,丙型, 药物疗法

Abstract: Objective To study the effects of anti-trberculosis drugs on liver functions of the tuberculosis patients complicated with hepatitis B virus(HBV)and hepatitis C virus(HCV)infectious.Methods Both groups of the tuberculosis patients complicated with HBV and HCV,and group of Tuberculosis patient without HBV and HCV complicated infectious were treated with an identical regimen of chemotherapy of anti-tuberculosis.The liver functions of patients in both groups were observed and compared during the courses of anti-trberculosis therapy.Results The liver injury rate in the group with complicated HBV and HCV was(50.0%)significantly higher than that in the patients without HBV and HCV complicated infectious(7.7%)(P<0.01),and the time of liver injury occurred and time for liver function to restore were also significantly different(P<0.05,P<0.01).However,The injury degree was not significantly different(P>0.05).Conclusion The incidence of liver injury of the tuberculosis patients complicated with both HBV and HCV is high,early occurred,and restore slow.During the anti-tuberculosis therapy ,but the injury degree maybe mild .It is necessary,however,to monitor liver function for those patients in a short period.

Key words: Tuberculosis,pulmonary, Hepatitis B and C virus Marker, Drug therapy